



30 April 2019

**Proteome Sciences plc
("Proteome Sciences" or the "Company")**

Result of Annual General Meeting (AGM)

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 2.30 p.m. today, all resolutions were duly passed.

A copy of the presentation given by the CEO, Jeremy Haigh, at the AGM will be available on the Company's website tomorrow.

For further information:

Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.